Back

Johnson Fistel investigates Erasca over alleged fiduciary-duty breaches

Verifying
  • Johnson Fistel is investigating Erasca officers and directors over alleged fiduciary-duty breaches.
  • Erasca disclosed Revolution Medicines' allegations against ERAS-0015 on April 27, 2026.
  • Shareholders continuously holding shares before January 14, 2025, may have standing for reforms.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.